ARVN Q4 2022 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+44.5% YoY

Gross Profit

$36M94.5% margin

Operating Income

-$75M-198.4% margin

Net Income

-$83M-218.2% margin

EPS (Diluted)

$-1.50

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$72M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$704M

Stockholders' Equity

$565M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$26M	+44.5%
Gross Profit	$36M	$25M	+45.1%
Operating Income	-$75M	-$54M	-38.6%
Net Income	-$83M	-$53M	-56.4%